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Running title: Treatment of enteric fever in South Asia 
Summary: This is the largest collection of enteric fever treatment data ever combined. The results, from  
trials conducted in Nepal since 2005, confirm that fluoroquinolones are failing for enteric fever treatment. 
The WHO enteric fever treatment guidelines should be modified.  
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Abstract 
Background 
Enteric fever, caused by Salmonella Typhi and Salmonella Paratyphi A, is the leading cause of bacterial 
febrile disease in South Asia.  
Methods 
Individual patient data from 2,092 subjects with enteric fever randomised into four trials in Kathmandu, 
Nepal was pooled. All trials compared gatifloxacin with a comparator drug: cefixime, chloramphenicol, 
ofloxacin, or ceftriaxone. Treatment outcomes were evaluated according to antimicrobial if S. 
Typhi/Paratyphi were isolated from blood. We additionally investigated the impact of changing bacterial 
antimicrobial susceptibility on outcome.  
Results 
Overall, 855 (41%) patients had either S. Typhi (n=581,28%) or S. Paratyphi A (n=274,13%) cultured 
from blood. There were 139 (6.6%) treatment failures with one death. Except for the last trial with 
ceftriaxone, the fluoroquinolone gatifloxacin was associated with equivalent or better fever clearance 
times and lower treatment failure rates in comparison to all other antimicrobials. However, we 
additionally found the minimum inhibitory concentrations (MIC) against fluoroquinolones have risen 
significantly since 2005 and were associated with increasing fever clearance times. Notably, all organisms 
were susceptible to ceftriaxone throughout the study period (2005-2014) and the MICs against 
azithromycin declined, confirming the utility of these alternative drugs for enteric fever treatment. 
Conclusion 
The World Health Organization and local government health ministries in South Asia still recommend 
fluoroquinolones as the drug of choice in the treatment of enteric fever. This policy should change based 
on the evidence provided here. Rapid diagnostics are urgently required given the large numbers of 
suspected enteric fever patients with a negative culture. 
Key words: antimicrobial resistance, typhoid, enteric fever, Nepal, fluoroquinolone 
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Introduction 
Enteric (typhoid) fever is a systemic infection caused by the Salmonella enterica serovars Typhi and 
Paratyphi A, B and C. Enteric fever is a significant cause of morbidity and mortality in low-income 
regions,1 and was responsible for an estimated 12.2 million disability adjusted life years (DALYs) and 
>190,000 deaths globally in 2010.2 The fatality rate of enteric fever is low (<1%), but is higher when 
antimicrobial therapy is delayed or unavailable.3 Therefore, antimicrobials are essential for the clinical 
management of enteric fever. Chloramphenicol, ampicillin, and cotrimoxazole were first line enteric fever 
treatments until the early 1990s when the increasing incidence of multidrug resistant (MDR; defined as 
resistance to these three antimicrobial drugs) S. Typhi organisms led to the use of fluoroquinolones.4,5 Yet 
organisms with reduced susceptibility against fluoroquinolones became a problem in Asia soon after their 
introduction.6,7 Recent phylogeographic analyses documenting an on-going epidemic of a global AMR S. 
Typhi lineage suggest that the potential for regional or global dispersal of a lineage exhibiting resistance 
to fluoroquinolones is now a real threat.8±10 In the absence of effective and accessible vaccines and lack of 
sanitation improvements, developing tailored antimicrobial therapy recommendations is critical to reduce 
morbidity and prevent disease transmission.  
 
In Kathmandu, Nepal, S. Typhi and S. Paratyphi A are the most commonly isolated organisms from the 
blood of febrile adults and children.11,12 Over the last decade we have conducted four randomised 
controlled trials (RCTs) evaluating enteric fever treatment in this endemic region.13±16 The aim of this 
study was to use the largest collection of individual patient data assembled to date from enteric fever 
treatment trials to evaluate the effect of treatment drug on differences in clinical outcome between S. 
Typhi and S. Paratyphi A infections and those with blood culture negative enteric fever. We further 
sought to compare the antimicrobial susceptibility profiles over time between S. Typhi and S. Paratyphi A 
isolates and investigate their impact on outcome. Generating an in-depth understanding of trends and 
clinical implications of AMR enteric fever should guide policymakers and clinicians in decisions 
regarding treatment in an era of rapidly diminishing therapeutic options. 
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Methods 
Ethical approval 
Written informed consent was required for participation in all trials, which was provided by a parent or 
adult guardian if a patient was aged <18 years. The Ethics Committee of the Nepal Health Research 
Council (NHRC) and the Oxford Tropical Research Ethics Committee (OxTREC) of the United Kingdom 
provided ethical approval for all four studies.  
 
Patient populations and study procedures 
Individual patient data for this study were derived from four RCTs conducted at Patan Hospital in, 
Kathmandu, Nepal between 2005 and 2014, the methods and results of which have been described 
previously.13±16 Patients presenting to the outpatient or emergency department with fever for >3 days with 
a clinical diagnosis of enteric fever (undifferentiated fever  >38°C with no focus of infection) were 
eligible. Patients were excluded if they were pregnant or lactating, were under two years of age or 
weighed <10kg, showed any signs of complications (jaundice, shock, gastrointestinal bleeding), 
hypersensitivity to the relevant trial drugs or had been treated with a study drug in the week prior to 
attending hospital. The study procedures between the four trials were comparable, however there was 
several minor protocol differences between studies (outlined in Table S1).  
 
Patients were randomly assigned to one of two arms in each trial. Each trial was composed of a 
gatifloxacin arm (10mg/kg/day, single dose orally for 7 days) and a comparator arm, which were: 
cefixime (20mg/kg/day, two doses orally for 7 days),13 chloramphenicol (75mg/kg/day, four divided oral 
doses for 14 days),14 ofloxacin (20mg/kg/day, two divided oral doses for 7 days)15 and ceftriaxone 
(intravenous; 60mg/kg [2-\HDUV@RUJNJ>\HDUV@).16 Gatifloxacin was the constant comparator 
because it is inexpensive and given once daily.  
 
Fever clearance time (FCT) was defined as the time from the first dose of a study drug until the 
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WHPSHUDWXUHGURSSHGWR.5oC and remained below this temperature for at least two days. The 
composite endpoint treatment failure summarised unfavourable outcomes and was defined as the 
occurrence of at least one of the following: persistent fever (FCT of more than seven days (trial 1 and 4) 
or more than ten days (trial 2 and 3) after treatment initiation), the need for rescue treatment, 
microbiological failure (blood culture positive for Salmonella) on day eight, relapse or disease-related 
complications within 31 days of treatment initiation or death. Blood was taken from all patients for 
microbiological culture on enrolment and on day eight for culture positive individuals or those with a 
potential relapse. 
 
Microbiological investigations have been described previously.13±16 Blood samples from adult patients 
were inoculated into media containing tryptone soya broth and sodium polyanethol sulphonate. For 
children, BacTEC Ped Plus/F bottles were used. Positive bottles were cultured onto MacConkey agar and 
presumptive Salmonella colonies were identified using biochemical tests and serotype-specific antisera. 
During all four trials, minimum inhibitory concentrations (MICs) were determined against the following 
antimicrobials unless otherwise noted: augmentin, ampicillin, amoxicillin, azithromycin (2006-2011), 
cefixime (2005), chloramphenicol, ciprofloxacin (2006-2014), ceftriaxone, gatifloxacin, naladixic acid, 
ofloxacin (2006-2014), cotrimoxazole (2006-2009, 2011-2014) and tetracycline by E-test (AB Biodisk, 
Sweden).  
 
Statistical analyses 
Data from the trials was combined and analysed using STATA v13.1 (College Station, Texas, USA). 
Plots were drawn in R v3.1.1 (R Foundation, Vienna, Austria) using the ggplot2 package. Demographics 
and clinical variables were tabulated and compared between serovars. Comparisons of clinical parameters 
between patient populations were structured as logistic regressions with the patient population (either 
culture positive/negative or S. Typhi/S. Paratyphi A) as the main covariate and adjustment for age stratum 
(binary: <\HDUV\HDUVMultivariable models with random effects were fitted to adjust for study 
7 
 
heterogeneity: (a) FCT was evaluated using Kaplan-Meier estimates and Cox proportional hazard models 
with treatment group, and age as covariates; (b) logistic regression was used to determine the odds of 
treatment failure between treatment arms, controlling for age and, (c) linear regression was used to 
evaluate the relationship between FCT and log2 MIC, also controlling for age. Generalized additive 
models (GAM, identity link, cubic spline) were used to examine potential non-linear trends of MIC over 
time... 
 
Results 
Baseline characteristics  
Between 2005 and 2014 there were 2,118 patients with clinically suspected enteric fever randomised into 
four trials; data from 2,092 (99%) patients were evaluated (Figure 1). Of these, 855 (41%) were culture 
positive for either S. Typhi (n=581, 28%) or S. Paratyphi A (n=274, 13%). Throughout the study period 
there were 139 (6.6%) treatment failures including one death. The median patient age was 17 years 
(interquartile range [IQR]: 10-23); 66% were male (Table 1). There was no significant difference in age 
between the culture negative and culture positive patients, however S. Typhi patients were significantly 
younger (median: 16 years, IQR: 9-21) than S. Paratyphi A patients (median: 19.5 years, IQR: 13-24) 
(p<0.001) (Table 2). There was no difference in the sex distribution between culture positive/culture 
negative or S. Typhi/S. Paratyphi A populations (Table 2).    
 
There were several significant differences in clinical history between patient populations after controlling 
for age (Table 2). Culture negative patients were significantly more likely to report coughing (40%) and 
vomiting (22%) than culture positive patients (31% and 17%, respectively). Culture positive patients, 
however, reported diarrhoea (24%) more often than culture negative patients (17%) in addition to a higher 
temperature (median: 39.0°C and 38.7°C, respectively). Amongst the culture positive patients, those with 
an S. Typhi infection were significantly more likely to report a history of anorexia (78%), coughing (33%) 
and diarrhoea (28%) in comparison to the S. Paratyphi A patients (71%, 25% and 15%, respectively) and 
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presented with higher temperatures (median: 39.0°C vs. 38.8°C). S. Paratyphi A patients were 
significantly more likely to report a history of previous typhoid illness (23%) compared to S. Typhi 
patients (12%). Additionally, there were several significant differences in haematology parameters 
between the culture negative/culture positive patients and the S. Typhi/S. Paratyphi A patients (Table 1), 
despite the majority of the values falling within normal ranges. AST and ALT were significantly elevated 
in the culture positive patients (median: 51 U/and median: 38 U/L, respectively) compared to culture 
negative patients (median: 42 U/L and median: 31 U/L, respectively).  
 
Treatment failure 
The number of patients failing treatment in each of the treatment arms is shown in Table 3.  Rates of 
failure between antimicrobial treatment arms were largely similar when stratified by microbiological 
culture result with a few notable exceptions. In comparison to gatifloxacin, culture positive patients were 
significantly more likely to fail treatment when administered cefixime (OR: 10.7, 95%CI: 3.72-30.61, 
p<0.001). Culture negative patients were more likely to fail with cefixime (OR: 7.13, 95%CI: 2.82-18.0, 
p<0.001), ceftriaxone (OR: 19.3, 95%CI: 8.02-46.5, p<0.001) and chloramphenicol (OR: 3.67, 95%CI: 
1.52-8.86, p=0.004) in comparison to gatifloxacin. 
 
Fever clearance times 
The FCTs of the various patient populations are shown in Figure 2 and Table 4. Amongst the culture 
positive patient population,  S. Typhi patients treated with cefixime (HR: 0.36, 95%CI: 0.25-0.54, 
p<0.001) and ceftriaxone (HR: 1.53, 95%CI: 1.01-2.31, p=0.043) had significantly longer FCTs than S. 
Typhi patients treated with gatifloxacin. In the culture positive patients, those infected with S. Typhi also 
had significantly longer FCTs than S. Paratyphi A patients when treated with cefixime (HR: 2.18, 95%CI: 
1.25-3.80, p=0.006) (Table 4). However, S. Paratyphi A infected patients had longer FCTs when treated 
with chloramphenicol compared to S. Typhi infected patients (HR: 0.069, 95%CI: 0.49-0.97, p=0.031). In 
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comparison to gatifloxacin, culture negative patients fared significantly worse when treated with cefixime 
(HR: 0.56, 95%CI: 0.43-0.71, p<0.001) and ceftriaxone (HR: 0.42, 95%CI: 0.31-0.57, p<0.001). 
 
Antimicrobial susceptibility trends 
As shown in Figure 3, the MICs for S. Paratyphi A were significantly higher than those for S. Typhi with 
all antimicrobials (p<0.001, Kruskal-Wallis), with the exception of cefixime (p=0.375). Figure 4 shows 
the MIC time trends by serovar, which were significantly non-linear over time for all antimicrobials in 
both serovars (GAM, p<0.001 with the exception of S. Paratyphi A/ciprofloxacin: p=0.052 and S. 
Paratyphi A/nalidixic acid: p=0.003). Most notably, the MICs against the fluoroquinolones rose 
significantly over time and the MICs against azithromycin declined between 2007 and 2010. Lastly, all 
isolates were susceptible to ceftriaxone throughout the study period. 
 
The impact of antimicrobial resistance on clinical outcomes 
Increasing MICs against fluoroquinolones led to longer FCT in S. Typhi patients. As shown in Figure 5, 
an increasing (log2) MIC was associated with longer FCTs in patients treated with gatifloxacin (number 
of hours increase in FCT for each 2-fold increase in MIC (ȕ)=8.1, 95%CI: 5.3-10.8, p<0.001) and 
RIOR[DFLQȕ .4, 95%CI: 2.2-14.5, p=0.008). Longer FCTs were also observed with increasing MICs 
against ciprofloxacin in S. Typhi patients treated with ofloxacin or gatifloxacin ȕ 6.88, 95%CI: 4.9-8.9, 
p<0.001). However, we found no significant association between FCT and (log2) MIC against the 
fluoroquinolones in the S. Paratyphi A patients (all p>0.05). Additionally, there was no significant 
association between FCT and MIC for the other antimicrobials tested. Lastly, patients infected with a S. 
Typhi isolate that was non-susceptible to FLSURIOR[DFLQ0,&.1ȝJP/ZHUHPRUHOLNHO\WRH[SHULHQFH
treatment failure (29/211, 13.7%) when treated with ofloxacin or gatifloxacin compared to patients 
infected with S. Typhi organisms susceptible to ciprofloxacin (MIC<0.1ȝJP/(2/79, 2.5%) (OR: 5.16, 
95%CI: 1.1-23.2, p=0.033). Conversely, we did not identify a similar relationship in those infected with 
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S. Paratyphi A (8/149 [5.4%] vs. 1/6 [16.7%], OR: 0.32, 95%CI: 0.03-3.15, p=0.329), the majority of 
which exhibited reduced susceptibility against ciprofloxacin 0,&.1ȝJP/ (211/221, 96%). 
 
Discussion 
Enteric fever remains the leading cause of febrile bacterial illness in Kathmandu.12 With alarming AMR 
rates, a lack of immunisation as a public health tool and slow sanitation improvements, tailored 
antimicrobial therapies for the prevailing AMR profiles are required. Using systematic longitudinal 
individual patient data we identified dynamic antimicrobial susceptibility profiles among S. Typhi and S. 
Paratyphi A isolates and a trend of increasing fluoroquinolone MICs correlating with poor outcome. This 
phenomenon was particularly apparent among S. Typhi patients. Although ceftriaxone was effective in 
treating culture confirmed enteric fever patients, we document poor clinical response in culture negative 
patients. These data suggest that careful consideration is required for antimicrobial therapy of patients 
with enteric fever. In addition, fluoroquinolones should not be recommended for empirical treatment of 
this infection in South Asia.17  
 
By combining the largest number of enteric fever patients from a single location we were able to identify 
several notable differences in both clinical presentation and clinical response between S. Typhi and S. 
Paratyphi A patients. Previous work conducted at the same centre found the two serovars to be clinically 
indistinguishable,18 we find that, after controlling for age, S. Typhi patients were more likely to report 
anorexia, diarrhoea and coughing and presented with a higher temperature.  
 
The precise mechanism driving the variability in MICs over time for both S. Typhi and S. Paratyphi A 
against several antimicrobials throughout 2005-2014 is unknown, but may be determined by local 
prescribing practices. This hypothesis is consistent with notable declines in MDR organisms in both 
Nepal and India after fluoroquinolones became the first choice of treatment.12,19,20 However, we predict a 
rapid rebound of MDR organisms with reversion to the prescribing of first line antimicrobials due to the 
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circulation of MDR plasmids in S. Typhi and other organisms.8,21  
 
Our study period captured dynamic changes in MICs against fluoroquinolones, particularly amongst S. 
Typhi isolates in more recent years. Through whole genome sequencing we have determined that this rise 
in MIC is associated with the emergence of an H58 variant with mutations in the DNA gyrase gene (gyrA) 
and the DNA topoisomerase IV gene (parC).10,16 Supporting these findings, we can conclusively show 
that FCTs and the rate of treatment failure increases with elevated MICs in S. Typhi patients treated with 
a fluoroquinolone, confirming results from small studies conducted elsewhere.7,22 However, although S. 
Paratyphi A isolates had significantly higher MICs against all tested fluoroquinolones in comparison to S. 
Typhi, poor outcome was not significantly associated with increasing MIC. We suggest continued 
surveillance of S. Paratyphi A in the region to monitor for the emergence of high-level fluoroquinolone 
resistant organisms similar to trends in the S. Typhi population. 
 
As highlighted in our most recent RCT, patients with suspected enteric fever who were blood culture 
negative were treated effectively with gatifloxacin, yet fared less well when treated with ceftriaxone.16 
The present analysis shows that ofloxacin also performs well in treating those with culture negative 
enteric fever, though due to the low sensitivity of blood culture for the detection of S. Typhi and S. 
Paratyphi A23, it is likely ofloxacin may have been effective against undetected enteric fever cases. 
However,  we have documented that a reasonable proportion (22%, 21/96) of patients enrolled in the third 
trial included in the present analysis14 who were blood culture negative were serologically positive for 
murine typhus.24 Doxycycline is considered the drug of choice for rickettsial infections, although it seems 
that fluoroquinolones may also have clinical activity.24  
 
In 2003 the WHO published guidelines recommending azithromycin, ceftriaxone or cefixime for 
quinolone-resistant S. Typhi or S. Paratyphi A infections.23 Azithromycin is safe and efficacious for the 
treatment of uncomplicated typhoid,25,26 and although there are no current clinical MIC breakpoints, the 
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majority of isolates (88%) here were susceptible, using the previously suggested cut-off of <16µg/mL.27 
The low MICs against ceftriaxone and rapid FCTs throughout the study period indicate that this drug is 
likely to be effective for culture confirmed enteric fever in Nepal. The cost and parenteral route of 
administration, however, make ceftriaxone less suitable for patient treatment in low and middle income 
countries, particularly as 60-90% of enteric fever patients are treated as outpatients.3 An alternative would 
be the oral third generation cephalosporin cefixime, however, our first trial, that compared gatifloxacin 
with cefixime had to be stopped early by the DSMB because of the high failure rate in the cefixime arm 
(26/77) compared to gatifloxacin arm (5/92; OR ~9), despite all strains being cefixime susceptible.13 Our 
analysis supports a recommendation for azithromycin or ceftriaxone for culture confirmed enteric fever 
and in the absence of rapid diagnostics for rickettsial infections,28 a combination of ceftriaxone and 
doxycycline in culture negative febrile patients in this setting.16 However, identification of Extended 
Spectrum Beta Lactamase (ESBL) producing S. Paratyphi A in India again suggests vigilance is required.  
 
Our study has limitations. First, the poor diagnostic sensitivity of blood culture may lead to a 
misclassification of a significant number of patients, though a proportion of culture negatives are likely to 
be positive for Rickettsia spp.; this was not directly assessed.24 Furthermore, by combining patients from 
individual RCTs with some differing definitions, the data became non-randomised, however we included 
a random effect of study to account for heterogeneity between studies and controlled for age. Therefore, 
strong associations, such as odds of treatment failure between cefixime and gatifloxacin in culture 
positive patients, may be reduced with the larger, non-randomised data. Additionally, we were unable to 
access pharmacy records to evaluate the relationship of prescribing patterns for febrile patients and MICs 
against common antimicrobials. Notwithstanding these limitations, these results from this largest 
collection of trials with patient recruitment spanning a decade in an endemic location with a high burden 
of disease will help to inform therapy recommendations.  
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In conclusion, poor sanitation, low vaccine uptake and the emergence of extensive ciprofloxacin-resistant 
S. Typhi in Kathmandu suggest that appropriate antimicrobial usage policies are required for limiting 
morbidity, mortality and transmission. In this large evaluation, we document shifting antimicrobial 
susceptibility profiles; an association between poor treatment outcome and S. Typhi MICs in patients 
treated with a fluoroquinolone and again highlight the need for better diagnostics for febrile diseases in 
this setting. We reiterate that fluoroquinolones should not be recommended for the empirical treatment of 
enteric fever in South Asia,8,29 and advocate the use of azithromycin or ceftriaxone, alongside surveillance 
for changes in AMR profiles.  
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Figure 1. Enrolment of patients into enteric fever treatment trials in Nepal 
Flow chart showing enrolment of patients into the four individual randomized controlled trials according 
to antimicrobial treatment and blood culture result  
 
Figure 2. Fever clearance time by treatment arm and culture result  
Fever clearance time (in days) is shown for S. Typhi, S. Paratyphi A and culture negative patients. 
Colours indicate the different treatment arms. CFX: cefixime; CHL: chloramphenicol; CRO: ceftriaxone; 
GAT: gatifloxacin; OFX: ofloxacin. 
 
Figure 3. Distribution of MICs against antimicrobials for S. Typhi and S. Paratyphi A  
MICs shown on a log2 scale against 12 antimicrobials for S. Typhi (blue) and S. Paratyphi A (orange). 
Lower, middle and upper horizontal dashed lines represent the current CLSI cut-offs for 
susceptible/intermediate and intermediate/resistant, respectively 30. 
 
Figure 4. MICs over time for S. Typhi and S. Paratyphi A 
MICs shown on a log2 scale for eight antimicrobials over 2005-2014. S. Typhi are shown in blue and S. 
Paratyphi A are shown in orange. The smoothed line is derived from the generalized additive model 
showing a non-linear increase in MICs over time, with the shaded region showing the 95% confidence 
interval. Lower, middle and upper horizontal dashed lines represent the current CLSI cut-offs for 
susceptible/intermediate and intermediate/resistant, respectively 30. 
 
Figure 5. Fever clearance time and MIC against fluoroquinolones for S. Typhi and S. Paratyphi A 
Fever clearance time in days is shown plotted against log2 MIC for gatifloxacin (left) and ofloxacin 
(right). S. Typhi isolates are shown in blue and S. Paratyphi A isolates are shown in orange. The lines 
represent the best-fit linear model with 95% confidence interval shown by the shaded region.  
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Table 1. Baseline characteristics of patients enrolled in four enteric fever treatment trials 
Characteristic 
Trial 1 Trial 2 Trial 3 Trial 4 Total 
N n (%) or median (IQR) N 
n (%) or median 
(IQR) N 
n (%) or median 
(IQR) N 
n (%) or median 
(IQR) N 
n (%) or median 
(IQR) 
Age (yr) 382 17 (9-23) 844 16 (9-22) 623 17 (9-23) 239 19 (15-23) 2,088 17 (10-23) 
Male sex 382 247 (64.7) 844 540 (64.0) 627 406 (64.8) 239 180 (75.3) 2,092 1,373 (65.6) 
Weight (kg) 382 45 (24-53) 842 42 (21-52) 627 45 (25-54) 237 50 (40-56) 2,088 45 (24-53) 
Duration of illness before 
admission (days) 382 5 (3-6) 844 5 (4-7) 625 5 (4-7) 180 5 (4-7) 2,031 5 (4-7) 
Treatment with antimicrobials in 
the past 2 weeks 379 238 (62.8) 724 694 (95.9) 623 428 (68.7) 210 109 (51.9) 1,936 1,469 (75.9) 
Previous history of typhoid 382 61 (16.0) 844 138 (16.4) 626 103 (16.5) 238 37 (15.5) 2,090 339 (16.2) 
Family history of typhoid 382 62 (16.2) 844 140 (16.6) 625 164 (26.2) 239 35 (14.6) 2,090 401 (19.2) 
Typhoid vaccination 382 2 (0.5) 844 0 (0) 625 0 (0) 238 11 (4.6) 2,089 13 (0.6) 
Temperature at admission (°C) 379 38.9 (38.3-39.5) 844 38.9 (38.2-39.4) 626 38.6 (38.2-39.0) 235 38.8 (38.3-39.4) 2,084 38.8 (38.2-39.4) 
Headache 382 370 (96.9) 844 749 (88.7) 627 541 (86.3) 239 211 (88.3) 2,092 1,871 (89.4) 
Anorexia 382 289 (75.7) 844 632 (74.9) 627 455 (72.6) 239 173 (72.4) 2,092 1,549 (74.0) 
Abdominal pain 382 32 (8.4) 844 33 (3.9) 626 25 (4.0) 235 62 (26.4) 2,087 152 (7.3) 
Cough 382 142 (37.2) 844 277 (32.8) 627 246 (39.2) 239 91 (38.1) 2,092 756 (36.1) 
Nausea 382 132 (34.6) 844 258 (30.6) 627 174 (27.8) 239 124 (51.9) 2,092 688 (32.9) 
Vomiting 382 57 (14.9) 844 172 (20.4) 627 118 (18.8) 239 69 (28.9) 2,092 416 (19.9) 
Diarrhoea 382 86 (22.5) 844 161 (19.1) 627 105 (16.7) 239 59 (24.7) 2,092 411 (19.6) 
Constipation 382 41 (10.7) 844 105 (12.4) 627 79 (12.6) 239 31 (13.0) 2,092 256 (12.2) 
Hepatomegaly 382 19 (5.0) 844 113 (13.4) 626 7 (1.1) 231 0 (0) 2,083 139 (6.7) 
Splenomegaly 382 35 (9.2) 844 119 (14.1) 626 6 (1.0) 231 2 (0.9) 2,083 162 (7.8) 
Haematocrit (%) 370 40 (37-44) 831 39 (36-43) 624 38 (36-42) 235 39 (36-43) 2,060 39 (36-43) 
Leucocyte count (x109/L) 370 7.0 (5.5-9.0) 831 6.3 (5.0-8.1) 624 6.0 (4.8-7.7) 239 5.9 (4.7-7.3) 2,064 6.3 (5.0-8.0) 
Platelet count (x109/L) 356 190 (160-235) 800 190 (164-226) 615 174 (145-216) 239 168 (150-209) 2,010 184 (153-220) 
AST (U/L) 373 47 (36-62) 835 45 (34-61) 624 47 (34-67) 233 49 (36-70) 2,065 46 (35-65) 
ALT (U/L) 373 33 (24-48) 836 29 (20-43) 624 37 (28-53) 234 45 (31-63) 2,067 34 (24-50) 
S. Typhi isolated 382 119 (31.2) 844 249 (29.5) 627 132 (21.1) 239 81 (33.9) 2,092 581 (27.8) 
S. Paratyphi A isolated 382 50 (13.1) 844 103 (12.2) 627 86 (13.7) 239 35 (14.6) 2,092 274 (13.1) 
No growth or culture negative 382 213 (55.8) 844 492 (58.3) 627 409 (65.2) 239 123 (51.5) 2,092 1,237 (59.1) 
 
Trials: 1 ± gatifloxacin/cefixime 13, 2 ± gatifloxacin/chloramphenicol 14, 3 ± gatifloxacin/ofloxacin 15, 4 ± gatifloxacin/ceftriaxone 16  
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Table 2. Demographic and clinical characteristics of culture negative, culture positive, Salmonella Typhi and Salmonella Paratyphi A patients 
Characteristic 
Culture negative Culture positive 
p value ^ 
S. Typhi S. Paratyphi A 
p value ^ 
N n (%) or median (IQR) N 
n (%) or median 
(IQR) N 
n (%) or median 
(IQR) N 
n (%) or median 
(IQR) 
Age (yr)* 1,236 17 (9-24) 852 17 (10-22) 0.692 578 16 (9-21) 274 19.5 (13-24) <0.001 
Male sex* 1,237 818 (66.1) 855 555 (64.9) 0.565 581 373 (64.2) 274 182 (66.4) 0.525 
Weight (kg) 1,234 44 (23-54) 854 46 (25-53) 0.854 580 43.5 (22-52) 274 49 (38-55) <0.001 
Duration of illness before admission 
(days) 1,203 5 (4-7) 828 5 (4-7) 0.500 565 5 (4-7) 263 5 (4-6) 0.102 
Treatment with antimicrobials in the 
past 2 weeks 1,146 861 (75.1) 790 608 (77.0) 0.330 532 414 (77.8) 258 194 (75.2) 0.440 
Previous history of typhoid 1,236 208 (16.8) 854 131 (15.3) 0.276 581 68 (11.7) 273 63 (23.1) <0.001 
Family history of typhoid 1,236 242 (19.6) 854 159 (18.6) 0.657 580 107 (18.4) 274 52 (19.0) 0.400 
Typhoid vaccination 1,234 9 (0.7) 855 4 (0.5) 0.511 581 1 (0.2) 274 3 (1.1) 0.073 
Temperature at admission (°C) 1,233 38.7 (38.1-39.2) 851 39 (38.4-39.5) <0.001 577 39 (38.5-39.5) 274 38.8 (38.2-39.2) <0.001 
Headache 1,237 1098 (88.8) 855 773 (90.4) 0.348 581 518 (89.2) 274 255 (93.1) 0.237 
Anorexia 1,237 903 (73.0) 855 646 (75.6) 0.190 581 451 (77.6) 274 195 (71.2) 0.036 
Abdominal pain 1,237 479 (38.7) 855 258 (30.2) 0.067 581 261 (44.9) 274 97 (35.4) 0.061 
Cough 1,237 495 (40.0) 855 261 (30.5) <0.001 581 193 (33.2) 274 68 (24.8) 0.011 
Nausea 1,237 394 (31.9) 855 294 (34.4) 0.310 581 198 (34.1) 274 96 (35.0) 0.853 
Vomiting 1,237 271 (21.9) 855 145 (17.0) 0.010 581 106 (18.2) 274 39 (14.2) 0.324 
Diarrhoea 1,237 210 (17.0) 855 201 (23.5) <0.001 581 161 (27.7) 274 40 (14.6) <0.001 
Constipation 1,237 154 (12.4) 855 102 (11.9) 0.775 581 63 (10.8) 274 39 (14.2) 0.114 
Hepatomegaly 1,234 84 (6.8) 849 55 (6.5) 0.847 578 40 (6.9) 271 15 (5.5) 0.804 
Splenomegaly 1,234 85 (6.9) 849 77 (9.1) 0.069 578 48 (8.3) 271 29 (10.7) 0.224 
Haematocrit (%) 1,219 39 (36-43) 841 39 (36-43) 0.573 569 39 (35-43) 272 40 (37-44) 0.006 
Leucocyte count (x109/L) 1,220 6.4 (5.0-8.6) 844 6.1 (4.9-7.5) <0.001 572 6.2 (4.9-7.5) 272 5.8 (4.8-7.2) 0.528 
Platelet count (x109/L) 1,187 187 (157-229) 823 180 (150-210) 0.002 555 180 (151-214) 268 180 (150-210) 0.469 
AST (U/L) 1,220 42 (32-59) 845 51 (40-69) <0.001 573 54 (42-71) 272 47 (37.5-66) 0.023 
ALT (U/L) 1,220 31 (21-46.5) 847 38 (28-53) <0.001 575 39 (28-53) 272 36 (28-49.5) 0.564 
 
^p-values derived from logistic regression (categorical variables) or linear regression (continuous variables) with outcome characteristic of interest and a  
covariate of culture positivity or serovar, controlling for age \HDUV\HDUV; *p-values derived XVLQJ)LVKHU¶VH[DFWWHVWIRUFDWHJRUical data and the 
Kruskal-Wallis test for continuous data (not controlled for age)
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Table 3. Proportion of enteric fever patients with treatment failure by culture result and treatment  
Treatment arm 
Culture negative Culture positive S. Typhi S. Paratyphi A 
Total n (%) Total n (%) Total n (%) Total n (%) 
Gatifloxacin 617 9 (1.5) 440 36 (8.2) 298 26 (8.7) 142 10 (7.0) 
Cefixime 105 10 (9.5) 77 26 (33.8) 54 19 (35.2) 23 7 (30.4) 
Ceftriaxone 65 15 (23.1) 54 4 (7.4) 38 3 (7.9) 16 1 (6.3) 
Chloramphenicol 243 12 (4.9) 175 14 (8.0) 125 11 (8.8) 50 3 (6.0) 
Ofloxacin 207 5 (2.4) 109 8 (7.3) 66 7 (10.6) 43 1 (2.3) 
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Table 4. Fever clearance time (FCT) (in hours) for four enteric fever patient populations by treatment  
Population 
Culture negative Culture positive S. Typhi S. Paratyphi A 
N Median FCT (IQR) range N 
Median FCT 
(IQR) range N 
Median FCT 
(IQR) range N 
Median FCT 
(IQR) range 
Overall 1178 41.3 (18.2-71.3) 1.0-425.5 810 
92.7 
(65.3-124.7) 1.0-496.0 549 
92.0 
(66.4-125) 1.0-496.0 261 
94.4 
(56.1-122.8) 1.0-349.0 
 
Treatment arm            
 
GAT 585 39.1 (17.0-68.0) 1.0-285.9 416 
90.9 
(64.3-116.9) 1.0-349.0 283 
90.8 
(67.4-117.3) 1.0-309.6 133 
91.9 
(55.8-116.0) 6.8-349.0 
 
CFX 96 66.5 (18.5-134.5) 4.0-324.0 69 
134.0 
(82.0-205.0) 16.0-496.0 47 
140.0 
(96.0-232.0) 40.0-496.0 22 
100.0 
(81.0-164.0) 16.0-214.0 
 
CRO 62 102.3 (31.5-161.5) 1.0-354.3 54 
73.5 
(46.0-112.8) 7.8-232.8 38 
82.6 
(54.0-117.5) 7.8-215.4 16 
53.1 
(43.3-83.0) 7.8-232.8 
 
CHL 239 41.5 (20.2-68.7) 1.0-304.5 169 
94.2 
(65.2-136.3) 2.8-327.4 120 
89.8 
(65.2-121.7) 2.8-327.4 49 
114.7 
(63.4-151.6) 4.4-262.8 
 
OFX 196 36.8 (17.9-66.4) 1.0-425.5 102 
94.8 
(56.0-122.3) 1.0-311.8 61 
89.8 
(48.0-115.4) 3.6-189.8 41 
104.4 
(71.5-141.6) 1.0-311.8 
 
GAT: gatifloxacin; CFX: cefixime; CRO: ceftriaxone; CHL: chloramphenicol; OFX: ofloxacin; IQR: interquartile range 
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